Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Sigma Planning Corp

Sigma Planning Corp lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,540 shares of the biotechnology company’s stock after selling 309 shares during the quarter. Sigma Planning Corp’s holdings in Sarepta Therapeutics were worth $1,282,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Manchester Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. raised its stake in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank lifted its position in shares of Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Sarepta Therapeutics during the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

SRPT has been the topic of a number of analyst reports. Guggenheim lifted their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. HC Wainwright restated a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 13th. StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Needham & Company LLC reissued a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research report on Monday, January 27th. Finally, Evercore ISI dropped their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $176.77.

Sarepta Therapeutics Stock Down 0.7 %

Shares of Sarepta Therapeutics stock opened at $105.56 on Tuesday. Sarepta Therapeutics, Inc. has a 12-month low of $101.15 and a 12-month high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a 50 day moving average price of $117.11 and a two-hundred day moving average price of $123.14. The stock has a market capitalization of $10.08 billion, a P/E ratio of 84.45 and a beta of 0.75.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares of the company’s stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.